Michael E. Thase, MD

CBT for Insomnia in Patients With Comorbid Depression and Insomnia

October 26, 2016

If a patient with depression continues to have problems sleeping even after their depression is treated, what is the best course of action? In this RCT involving patients already...

Rachel Manber , Michael E. Thase , Stephen R. Wisniewski , et al

Article

Nocturnal Wakefulness and Suicide

June 22, 2016

Insomnia and nightmares have been shown to increase the risk for suicidal ideation and suicide. Could simply being awake at night be a risk factor as well? Perlis et...

Michael E. Thase , David F. Dinges , Mathias Basner , et al

Educational Activity

How Does Understanding Mechanism of Action Help Clinicians Personalize Antidepressant Treatment Choices?

February 24, 2016

Michael E. Thase

Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

David E. Kemp , Joseph R. Calabrese , Andrew A. Nierenberg , et al

Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

Joseph R. Calabrese , Andrew A. Nierenberg , Michael E. Thase , et al

Supplement Article

Managing Medical Comorbidities in Patients With Depression to Improve Prognosis

January 27, 2016

Michael E. Thase

Educational Activity

What Are the Mechanisms of Action of Current Antidepressant Treatments?

December 23, 2015

Michael E. Thase

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Robert D. McQuade , Margaretta Nyilas , William H. Carson , et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Robert D. McQuade , Margaretta Nyilas , William H. Carson , et al

Educational Activity

Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression

September 23, 2015

Michael E. Thase , Thomas L. Schwartz

Academic Highlights

Choosing Medications for Treatment-Resistant Depression

June 24, 2015

What can you do for your patients with depression who show partial response or no response to treatment? Follow a discussion by expert faculty about how altering levels of...

Michael E. Thase , Thomas L. Schwartz

Commentary

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

January 28, 2015

Michael E. Thase

CBT for Insomnia in Patients With Comorbid Depression and Insomnia

Nocturnal Wakefulness and Suicide

How Does Understanding Mechanism of Action Help Clinicians Personalize Antidepressant Treatment Choices?

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

Managing Medical Comorbidities in Patients With Depression to Improve Prognosis

What Are the Mechanisms of Action of Current Antidepressant Treatments?

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression

Choosing Medications for Treatment-Resistant Depression

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

ELSEWHERE:

FOLLOW US:

Michael E. Thase, MD

CBT for Insomnia in Patients With Comorbid Depression and Insomnia

Nocturnal Wakefulness and Suicide

How Does Understanding Mechanism of Action Help Clinicians Personalize Antidepressant Treatment Choices?

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

Managing Medical Comorbidities in Patients With Depression to Improve Prognosis

What Are the Mechanisms of Action of Current Antidepressant Treatments?

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression

Choosing Medications for Treatment-Resistant Depression

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles